Bristol Myers Reports Interim Phase 1 CAR T Data in Multiple Sclerosis

Bristol Myers Squibb reported interim zola-cel data, including safety consistent with prior trials, one Grade 5 septic pneumonia in haRMS, complete B-cell depletion, and all 60/60 DL2 patients off DMTs at last follow-up.